6 Oral: ZW220, a NaPi2b-directed topoisomerase I inhibitor Antibody-Drug Conjugate, demonstrates compelling preclinical activity in NSCLC, ovarian and uterine cancer models, with a favorable toxicology profile in non-human primates
Titel:
6 Oral: ZW220, a NaPi2b-directed topoisomerase I inhibitor Antibody-Drug Conjugate, demonstrates compelling preclinical activity in NSCLC, ovarian and uterine cancer models, with a favorable toxicology profile in non-human primates
Auteur:
Hernandez, A. Urosev, D. Wong, J. Lawn, S. Wu, K. Fu, L. Stahl, K. Lasalle, M. Alonzo, D.A. Yang, L. Sagoe-Wagner, A.P. Degefie, L. Kim, C. Wu, A. Chen, C.W. Higgins, R. Petersen, M. Colombo, R. Barnscher, S.D. Rich, J.R.